EHA 2025 | What are the latest updates from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL?

During the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub was pleased to speak to Gareth Gregory, Monash University, Melbourne, AU. We asked about the latest updates from the STARGLO trial (NCT04408638) of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

In this interview, Gregory shares the efficacy and safety outcomes from the phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL. Gregory covers the updated 2-year follow-up results, highlighting sustained survival benefits and manageable safety profile for Glofit-GemOx. He concludes that Glofit-GemOx offers durable remissions and is a potential off-the-shelf treatment option for autologous stem cell transplant (ASCT)-ineligible patients with R/R DLBCL. 

During the interview, Gregory shared the following key points¹:

• Patients with R/R DLBCL usually have a poor prognosis, and historically the only pathways with a meaningful likelihood of long-term remission and/or cure have been cellular therapies.

• The landscape is changing rapidly with the availability of second-line CAR T-cell therapies for patients progressing within 12 months; however, there is an unmet need for patients who are ineligible for or don’t have access to CAR T-cell therapies, and those who have comorbidities or are of advanced age and are ineligible for chemotherapy intensification and ASCT.

• STARGLO is a randomized, multicenter, phase III trial evaluating fixed-duration Glofit-GemOx vs R-GemOx in ASCT-ineligible patients with R/R DLBCL.

• A total of 274 patients were enrolled (Glofit-GemOx, n = 183; R-GemOx, n = 91), with 62.8% having one prior line of therapy and 55.8% being primary refractory.

• With a median follow-up of 24.7 months, the overall survival for patients who received Glofit-GemOx has not been reached.

• A landmark analysis of patients in complete remission at the end of induction chemo-immunotherapy showed that 89% of these patients are still alive at 12 months, and that 82% of those patients who achieved a complete remission at end of treatment maintained their complete remission to 12 months.

• The safety profile of Glofit-GemOx remained consistent, with no new safety signals. 

• In summary, STARGLO demonstrates that Glofit-GemOx provides durable remissions and a clinically meaningful overall survival benefit with manageable toxicity in ASCT-ineligible patients with R/R DLBCL.

• Results from this trial challenge the classic paradigm that all pathways to cure need to involve a cellular therapy and indicate a potential off-the-shelf regimen that has a meaningful likelihood of achieving durable remissions that may equate to cures going forward.

This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.